JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB282458

重组Anti-PD-L1抗体[RM1012]

Anti-PD-L1 antibody [RM1012]

  • BOND RX™ Validated
  • 20ul selling size
  • RabMAb
  • Recombinant
  • KO Validated
  • 了解详情

Be the first to review this product! Submit a review

|

(6 Publications)

Rabbit Recombinant Multiclonal PD-L1 antibody. Suitable for ICC/IF, IP, Flow Cyt, WB, IHC-P, I-ELISA and reacts with Human, Recombinant fragment samples. Cited in 6 publications.

查看别名

CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1

10 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [RM1012] (AB282458)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [RM1012] (AB282458)

Immunohistochemical analysis of paraffin-embedded Human lung cancer tissue labelling PD-L1 with ab282458 at 1/500 (0.876 ug/ml) dilution followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection). Positive staining on human lung cancer. The section was incubated with ab282458 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [RM1012] (AB282458)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [RM1012] (AB282458)

Immunohistochemical analysis of paraffin-embedded Human tonsil tissue labelling PD-L1 with ab282458 at 1/500 (0.876 ug/ml) dilution followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection). Positive staining on human tonsil. The section was incubated with ab282458 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [RM1012] (AB282458)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [RM1012] (AB282458)

Immunohistochemical analysis of paraffin-embedded Human breast cancer tissue labelling PD-L1 with ab282458 at 1/500 (0.876 ug/ml) dilution followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) . Positive staining on human breast cancer. The section was incubated with ab282458 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND® RX instrument Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) .

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [RM1012] (AB282458)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [RM1012] (AB282458)

Immunohistochemical analysis of paraffin-embedded Human placenta tissue labelling PD-L1 with ab282458 at 1/500 (0.876 ug/ml) dilution followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) . Positive staining on human placenta. The section was incubated with ab282458 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND® RX instrument Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) .

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins

Immunoprecipitation - Anti-PD-L1 antibody [RM1012] (AB282458)
  • IP

Supplier Data

Immunoprecipitation - Anti-PD-L1 antibody [RM1012] (AB282458)

PD-L1 was immunoprecipitated from 0.35 mg NCI-H1975 (Human adenocarcinoma lung epithelial cell) whole cell lysate with ab282458 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab282458 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.

Lane 1 : NCI-H1975 (Human adenocarcinoma lung epithelial cell) whole cell lysate 10 ug

Lane 2 : ab282458 IP in NCI-H1975 whole cell lysate

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab282458 in NCI-H1975 whole cell lysate

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 32 seconds

All lanes:

Immunoprecipitation - Anti-PD-L1 antibody [RM1012] (ab282458)

Predicted band size: 33 kDa

Observed band size: 40-60 kDa

false

Western blot - Anti-PD-L1 antibody [RM1012] (AB282458)
  • WB

Supplier Data

Western blot - Anti-PD-L1 antibody [RM1012] (AB282458)

Lysates/proteins at 20 μg per lane.

Performed under reducing conditions.

False colour image of Western blot : Anti-PD-L1 antibody [RM1012] (ab282458) staining at 1/10, 000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red.

In Western blot, ab282458 was shown to bind specifically to PD-L1. Target band was observed at 40-60 kDa in wild-type A549 treated with IFN gamma cell lysates with no signal observed at this size in PD-L1 knockout cell line ab267054 (knockout cell lysate ab256831). To generate this image, wild-type and CD274 (PD-L1) knockout A549 cell lysates were analyzed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-PD-L1 antibody [RM1012] (ab282458) at 1/10000 dilution

Lane 1:

Untreated CD274 (PD-L1) KO A549 (Human lung carcinoma epithelial cell) cell lysate at 20 µg

Lane 2:

CD274 (PD-L1) KO A549 treated with 100 ng/ml human IFN gamma for 48 hours cell lysate at 20 µg

Lane 3:

Untreated wild-type A549 cell lysate at 20 µg

Lane 4:

Wild-type A549 treated with 100ng/ml human IFN gamma for 48 hours cell lysate at 20 µg

Lane 5:

MDA-MB-231 (Human breast adenocarcinoma epithelial cell) cell lysate at 20 µg

Lane 6:

NCI-H1975 (Human adenocarcinoma lung epithelial cell) cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/100000 dilution

Predicted band size: 33 kDa

Observed band size: 40-60 kDa

false

Exposure time: 3min

Western blot - Anti-PD-L1 antibody [RM1012] (AB282458)
  • WB

Supplier Data

Western blot - Anti-PD-L1 antibody [RM1012] (AB282458)

Blocking and Diluting buffer and concentration : 5% NFDM/TBST.

Low expression control : MCF7 (PMID : 28184013, 31741201).

All lanes:

Western blot - Anti-PD-L1 antibody [RM1012] (ab282458) at 1/1000 dilution

Lane 1:

NCI-H1975 (Human adenocarcinoma lung epithelial cell) whole cell lysate at 20 µg

Lane 2:

MDA-MB-231 (Human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Lane 3:

MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Lane 4:

Human placenta lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 33 kDa

Observed band size: 40-60 kDa

false

Flow Cytometry - Anti-PD-L1 antibody [RM1012] (AB282458)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-PD-L1 antibody [RM1012] (AB282458)

Flow cytometric analysis of CHO-S (Chinese hamster ovary epithelial cell (Blue)) / CHO-PDL1 (PD-L1 stably expessed Chinese hamster ovary epithelial cell) (Red)) cells labelling PD-L1 with ab282458 at 1/50 dilution (1ug). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) at 1/2000 dilution was used as the secondary antibody. Gated on viable cells.

Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [RM1012] (AB282458)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [RM1012] (AB282458)

Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized CHO-PDL1 cells labelling PD-L1 with ab282458 at 1/1000 (0.438 ug/ml) dilution, followed by ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) antibody at 1/1000 dilution (Green). Confocal image showing membranous staining in CHO-PDL1 cells and no staining in CHO-S cells.

ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/200 2.5ug/ml dilution (Red). The Nuclear counterstain was DAPI (Blue).

Secondary antibody only control : Secondary antibody is ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/1000 dilution.

Indirect ELISA - Anti-PD-L1 antibody [RM1012] (AB282458)
  • I-ELISA

Supplier Data

Indirect ELISA - Anti-PD-L1 antibody [RM1012] (AB282458)

ELISA using ab282458 at varying antibody concentrations and antigen concentration at 1000 ng/ml. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) (1/2500) was used as the secondary antibody.

不同偶联物与剂型 (1)

  • Carrier free

    Anti-PD-L1 antibody [RM1012] - BSA and Azide free

关键信息

宿主种属

Rabbit

克隆

Multiclonal

克隆号

RM1012

亚型

IgG

不含载体蛋白

No

反应种属

Human

应用

IP, IHC-P, I-ELISA, Flow Cyt, WB, ICC/IF

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/1000", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1/50", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/10000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/500", "IHCP-species-notes": "<p></p>", "IELISA-species-checked": "guaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "" }, "Mouse": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "IELISA-species-checked": "notRecommended", "IELISA-species-dilution-info": "", "IELISA-species-notes": "" }, "Rat": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "IELISA-species-checked": "notRecommended", "IELISA-species-dilution-info": "", "IELISA-species-notes": "" }, "Recombinant fragment": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "<p></p>" } } }

产品详情

What are recombinant multiclonals?
Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including:

  • - The sensitivity of polyclonal antibodies by recognising multiple epitopes
  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

View our range of recombinant multiclonal antibodies.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein A
存储溶液
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
运输条件
Blue Ice
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
See full target information CD274

文献 (6)

Recent publications for all applications. Explore the full list and refine your search

Cancer cell international 25:225 PubMed40544264

2025

Comprehensive analysis of single-cell and bulk RNA sequencing data unveils antigen-presenting and processing fibroblasts and establishes a predictive model in gastric cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Chenggang Zhang,Fangqi Chen,Jie Li,Yixuan He,Juan Sun,Zicheng Zheng,Guanmo Liu,Yihua Wang,Weiming Kang,Xin Ye

Gut microbes 17:2512900 PubMed40469055

2025

Chikungunya virus drives gut microbiota shifts and IFN-Mediated intestinal repair: insights into microbiota-immune interplay.

Applications

Unspecified application

Species

Unspecified reactive species

Hongyu Chen,Kaiyun Ding,Cong Tang,Jingwen Xu,Fengyuan Zhang,Yao Yan,Bai Li,Yanan Zhou,Yun Yang,Hao Yang,Qing Huang,Wenhai Yu,Haixuan Wang,Daoju Wu,Shuaiyao Lu,Hongqi Liu

iScience 27:110544 PubMed39206147

2024

Proteogenomic characterization of pancreatic neuroendocrine tumors uncovers hypoxia and immune signatures in clinically aggressive subtypes.

Applications

Unspecified application

Species

Unspecified reactive species

Atsushi Tanaka,Makiko Ogawa,Yihua Zhou,Yusuke Otani,Ronald C Hendrickson,Matthew M Miele,Zhuoning Li,David S Klimstra,Julia Y Wang,Michael H Roehrl

Computational and structural biotechnology journal 23:990-1004 PubMed38404710

2024

Comprehensive integration of single-cell RNA and transcriptome RNA sequencing to establish a pyroptosis-related signature for improving prognostic prediction of gastric cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Jie Li,Tian Yu,Juan Sun,Mingwei Ma,Zicheng Zheng,Weiming Kang,Xin Ye

Cancers 15: PubMed37894415

2023

Astragaloside IV Attenuates Programmed Death-Ligand 1-Mediated Immunosuppression during Liver Cancer Development via the miR-135b-5p/CNDP1 Axis.

Applications

Unspecified application

Species

Unspecified reactive species

Yang Ma,Yan Li,Taotao Wu,Yingshuai Li,Qi Wang

International journal of molecular medicine 51: PubMed36601741

2023

Upregulation of MTHFD2 is associated with PD‑L1 activation in bladder cancer via the PI3K/AKT pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Xinxi Deng,Xiaoqiang Liu,Bing Hu,Jianyun Liu,Bin Fu,Wensheng Zhang
View all publications

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com